000291278 001__ 291278
000291278 005__ 20241030141748.0
000291278 0247_ $$2doi$$a10.3390/cancers16122273
000291278 0247_ $$2pmid$$apmid:38927978
000291278 037__ $$aDKFZ-2024-01361
000291278 041__ $$aEnglish
000291278 082__ $$a610
000291278 1001_ $$0P:(DE-HGF)0$$aHoegen-Saßmannshausen, Philipp$$b0$$eFirst author
000291278 245__ $$aClinical Outcomes of Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Adrenal Metastases from a Single Institution.
000291278 260__ $$aBasel$$bMDPI$$c2024
000291278 3367_ $$2DRIVER$$aarticle
000291278 3367_ $$2DataCite$$aOutput Types/Journal article
000291278 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719490964_13581
000291278 3367_ $$2BibTeX$$aARTICLE
000291278 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291278 3367_ $$00$$2EndNote$$aJournal Article
000291278 500__ $$a#EA:E050#LA:E050#
000291278 520__ $$a(1) Background: Recent publications foster stereotactic body radiotherapy (SBRT) in patients with adrenal oligometastases or oligoprogression. However, local control (LC) after non-adaptive SBRT shows the potential for improvement. Online adaptive MR-guided SBRT (MRgSBRT) improves tumor coverage and organ-at-risk (OAR) sparing. Long-term results of adaptive MRgSBRT are still sparse. (2) Methods: Adaptive MRgSBRT was performed on a 0.35 T MR-Linac. LC, overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicity were assessed. (3) Results: 35 patients with 40 adrenal metastases were analyzed. The median gross tumor volume was 30.6 cc. The most common regimen was 10 fractions at 5 Gy. The median biologically effective dose (BED10) was 75.0 Gy. Plan adaptation was performed in 98% of all fractions. The median follow-up was 7.9 months. One local failure occurred after 16.6 months, resulting in estimated LC rates of 100% at one year and 90% at two years. ORR was 67.5%. The median OS was 22.4 months, and the median PFS was 5.1 months. No toxicity > CTCAE grade 2 occurred. (4) Conclusions: LC and ORR after adrenal adaptive MRgSBRT were excellent, even in a cohort with comparably large metastases. A BED10 of 75 Gy seems sufficient for improved LC in comparison to non-adaptive SBRT.
000291278 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000291278 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291278 650_7 $$2Other$$aMR-guided radiotherapy
000291278 650_7 $$2Other$$aMR-linac
000291278 650_7 $$2Other$$aNSCLC
000291278 650_7 $$2Other$$aSABR
000291278 650_7 $$2Other$$aadaptive radiotherapy
000291278 650_7 $$2Other$$agating
000291278 650_7 $$2Other$$amelanoma
000291278 650_7 $$2Other$$aoligometastasis
000291278 650_7 $$2Other$$aoligoprogression
000291278 650_7 $$2Other$$aonline adaptation
000291278 7001_ $$aJessen, Inga$$b1
000291278 7001_ $$aBuchele, Carolin$$b2
000291278 7001_ $$aSchlüter, Fabian$$b3
000291278 7001_ $$aRippke, Carolin$$b4
000291278 7001_ $$aRenkamp, Claudia Katharina$$b5
000291278 7001_ $$0P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aWeykamp, Fabian$$b6$$udkfz
000291278 7001_ $$aRegnery, Sebastian$$b7
000291278 7001_ $$aLiermann, Jakob$$b8
000291278 7001_ $$00000-0001-7087-9581$$aMeixner, Eva$$b9
000291278 7001_ $$aHoeltgen, Line$$b10
000291278 7001_ $$00000-0003-0150-1328$$aEichkorn, Tanja$$b11
000291278 7001_ $$aKönig, Laila$$b12
000291278 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b13$$udkfz
000291278 7001_ $$aKlüter, Sebastian$$b14
000291278 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b15$$eLast author$$udkfz
000291278 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers16122273$$gVol. 16, no. 12, p. 2273 -$$n12$$p2273$$tCancers$$v16$$x2072-6694$$y2024
000291278 8564_ $$uhttps://inrepo02.dkfz.de/record/291278/files/cancers-16-02273.pdf
000291278 8564_ $$uhttps://inrepo02.dkfz.de/record/291278/files/cancers-16-02273.pdf?subformat=pdfa$$xpdfa
000291278 909CO $$ooai:inrepo02.dkfz.de:291278$$pVDB
000291278 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000291278 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000291278 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000291278 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000291278 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000291278 9141_ $$y2024
000291278 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000291278 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000291278 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000291278 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000291278 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000291278 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000291278 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000291278 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000291278 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000291278 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000291278 980__ $$ajournal
000291278 980__ $$aVDB
000291278 980__ $$aI:(DE-He78)E050-20160331
000291278 980__ $$aI:(DE-He78)HD01-20160331
000291278 980__ $$aUNRESTRICTED